Modulation of the urokinase receptor in human colon cell lines by N,N-dimethylformamide.
The present study documents the effect of the planar, polar differentiation promoter N,N-dimethylformamide (DMF) on urokinase binding to colon carcinoma cells. Exposure of the colon carcinoma cell lines to the agent resulted in enhanced specific binding of radioactive urokinase to all cells tested. Insulin binding to the cells was, however, unaffected by DMF. A DMF exposure period of 45 h was required to observe maximum urokinase binding to two representative cell lines FET and RKO. Optimal stimulation of both cell lines occurred with 0.8% DMF. Scatchard analysis revealed the dissociation constants to be unchanged by the agent with the increased binding of radioactive plasminogen activator reflecting an up-regulation of binding sites. In this regard, the cell line RKO upon exposure to DMF, displayed approx. 700,000 receptors/cell, the highest value published, to date, for any cell line.
Boyd
D
D
Bristol-Baylor Laboratory, Baylor College of Medicine, Houston, TX 77030.
Florent
G
G
Murano
G
G
Brattain
M
M
D002460:Cell Line; D003106:Colon / Q000378:metabolism*; D004126:Dimethylformamide / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D011972:Receptor, Insulin / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000378:metabolism*; D055293:Receptors, Urokinase Plasminogen Activator; D013997:Time Factors; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*
C524898:PLAUR protein, human; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D004126:Dimethylformamide; D011972:Receptor, Insulin; D014568:Urokinase-Type Plasminogen Activator